Less Ads, More Data, More Tools Register for FREE

Pin to quick picksUnicorn Asset Management Regulatory News (UAV)

Share Price Information for Unicorn Asset Management (UAV)

Share Price is delayed by 15 minutes
Get Live Data
70.00    0.00 (0.00%)
Bid:
67.00
Ask:
73.00
Spread: 6.00 (8.955%)
Market Cap: £180.27m
UAV Live PriceLast checked at - London Stock Exchange

Intraday Unicorn Asset Management Share Chart

Interim Management Statement

23 Jul 2020 12:51

RNS Number : 9204T
Unicorn AIM VCT PLC
23 July 2020
 

Unicorn AIM VCT plc ("the Company")

LEI: 21380057QDV7D34E9870

Interim Management Statement 

For the period from 1 April 2020 to 30 June 2020

 

Introduction

 

This voluntary Interim Management Statement (IMS) covers the three month period ended 30 June 2020, together with relevant information up to the date of publication. 

 

Investment Objective

 

The Company's objective is to provide Shareholders with an attractive return from a diversified portfolio of investments, predominantly in the shares of AIM quoted companies, by maintaining a steady flow of dividend distributions to Shareholders from the income as well as capital gains generated by the portfolio.

 

It is also the objective that the Company should continue to qualify as a Venture Capital Trust ("VCT"), so that Shareholders benefit from the taxation advantages that this brings. To achieve this, at least 80% of the Company's total assets are to be invested in qualifying investments of which 70% by VCT value (30% in respect of investments made before 6 April 2018 from funds raised before 6 April 2011) must be in ordinary shares, which carry no preferential rights (save as permitted under VCT rules) to dividends or return of capital and no rights to redemption.

 

Performance

 

Net asset value per share recovered strongly in the period under review, as equity markets rallied following the steep declines triggered by the spread of the COVID-19 pandemic.

As at 30 June 2020, the unaudited net asset value was 159.2 pence per share, which represents an increase of 24.0% on the unaudited closing net asset value of 128.4 pence per share as at 31 March 2020. By comparison, the FTSE AIM All-Share Index generated a total return of +29.7%, while the FTSE All-Share Index delivered a total return of 10.2% over the same period.

The performance of the Company's diverse portfolio of investments, has been largely resilient throughout the rapidly evolving Covid-19 crisis. It is encouraging to report that a number of our investee companies have been actively engaged in helping to combat the worst impacts of the pandemic. Businesses such as Abcam, Avacta, Genedrive, Omega Diagnostics and Tristel are all currently working to help ease the negative effects of the virus; either by helping to find a cure, developing testing kits or by providing disinfectant solutions to the healthcare sector. The Company has limited exposure to businesses dependent upon consumer spending, which has insulated Shareholders from the worst of the equity market falls experienced during the earlier part of 2020.

The portfolio remains predominantly composed of investments in businesses listed on the Alternative Investment Market (AIM). Many of these investee companies are relatively mature and, typically have remained profitable throughout the difficulties experienced since the start of 2020.

Deal flow has begun to improve as the period of strict lockdown appears to be reaching an end. Importantly, the rate of new investment required to meet all key HMRC tests has also been maintained. Following the recent closure of the fully subscribed Offer for Subscription, we have substantial cash available to deploy in the investment opportunities that pass the thorough due diligence process. It is important however, to remind Shareholders and potential new investors in the Company, that the new capital raised will, by regulatory necessity, be targeted at younger, less well-established businesses. Early stage, scale-up businesses tend to be loss-making and therefore more risky in investment terms. Our focus on providing scale-up capital has become even more important and relevant to early-stage businesses during the current crisis, however it should be noted that, despite the improved availability of State-aided capital, not all of them will be successful.

Despite the increased risks associated with early stage investment and the uncertainty created by the unexpected onset of a worldwide pandemic, the Investment Manager is confident that the portfolio, as a whole, offers the prospect of delivering attractive total returns over the longer term.

At the period end, an estimated 88% of total assets (by VCT value and excluding new capital) were invested in VCT qualifying companies.

Material Transactions

During the period under review, 2 follow-on VCT qualifying investments were made at a total cost of £0.5 million. In addition, subsequent to the period end, one new VCT qualifying investment, amounting to £2.0 million, was completed.

In aggregate, approximately £2.6 million was raised from the partial disposal of 4 holdings during the period. The usual purpose of such disposals is threefold; to ensure stock specific risk is contained, to lock in capital profits for future distribution to Shareholders via dividend payments and to help manage liquidity requirements. In addition, one holding was sold in its entirety as a result of M&A activity, realising proceeds of £1.9 million and crystallising a capital profit on disposal of £1.4 million.

Top Ten Holdings as at 30 June 2020

Stock

% of net assets

Interactive Investor

8.7%

Hasgrove plc

7.0%

Abcam

7.0%

Tracsis plc

4.4%

Tristel plc

2.9%

Anpario

2.9%

Mattioli Woods plc

2.9%

Renalytix AI

2.7%

Cohort plc

2.6%

MaxCyte Inc

2.4%

Total

43.5%

 

Share Buy-Backs

 

During the period from 1 April 2020 to 30 June 2020, the Company bought back 447,110 of its own Ordinary Shares for cancellation, at an average price of 110.0 pence per share. As at 30 June 2020, there were 147,391,486 Ordinary Shares in issue. After the period end, a further 631,281 Ordinary Shares were purchased for cancellation at a price of 129.5 pence per share.

 

Dividends

As previously advised, the Board declared an interim dividend of 3.0 pence per share in respect of the Company's half-year ended 31 March 2020. This interim dividend will be paid on 12 August 2020 to Shareholders who were on the register on 17 July 2020.

Material Events

The Offer for Subscription was fully subscribed and closed on 11 June 2020, having raised £24.2 million net of expenses. There were no other material events during the period from 1 April 2020 to 30 June 2020.

 

Chris Hutchinson

Unicorn Asset Management

Investment Manager

 

23 July 2020

This information is provided by RNS, the news service of the London Stock Exchange. RNS is approved by the Financial Conduct Authority to act as a Primary Information Provider in the United Kingdom. Terms and conditions relating to the use and distribution of this information may apply. For further information, please contact rns@lseg.com or visit www.rns.com.
 
END
 
 
STRDZGZNMFRGGZM
Date   Source Headline
23rd Jul 202012:51 pmRNSInterim Management Statement
17th Jul 20207:36 amRNSTransaction in Own Shares
7th Jul 20203:54 pmRNSNet Asset Value(s)
1st Jul 202010:20 amRNSTotal Voting Rights
22nd Jun 20202:46 pmRNSTotal Voting Rights
22nd Jun 20202:45 pmRNSDirector/PDMR Shareholding
22nd Jun 20208:00 amRNSIssue of Equity
18th Jun 20203:39 pmRNSNet Asset Value(s)
12th Jun 20209:39 amRNSOffer Update – Close of Applications for Offer
4th Jun 20209:59 amRNSNet Asset Value(s)
18th May 20205:08 pmRNSDirectorate Change
18th May 20203:52 pmRNSHalf-year Report
6th May 20205:33 pmRNSNet Asset Value(s)
1st May 202011:03 amRNSTotal Voting Rights
9th Apr 20205:32 pmRNSTransaction in Own Shares
6th Apr 20204:36 pmRNSDirector/PDMR Shareholding
6th Apr 20209:43 amRNSTotal Voting Rights
6th Apr 20207:00 amRNSIssue of Equity
1st Apr 20205:06 pmRNSNet Asset Value(s)
26th Mar 202010:43 amRNSPublication of Suppl.Prospcts
25th Mar 20202:33 pmRNSNet Asset Value and Offer Update
24th Mar 20206:28 pmRNSNet Asset Value(s)
17th Mar 20207:00 amRNSStatement re Offer for Subcription
11th Mar 202010:04 amRNSNet Asset Value(s)
2nd Mar 202011:05 amRNSTotal Voting Rights
11th Feb 202012:35 pmRNSOffer for Subscription and Issue of Prospectus
6th Feb 202011:51 amRNSIssue of Equity
4th Feb 20205:39 pmRNSNet Asset Value(s)
3rd Feb 202010:47 amRNSTotal Voting Rights
30th Jan 20205:34 pmRNSResult of AGM
28th Jan 20209:25 amRNSInterim Management Statement
20th Jan 20209:50 amRNSTransaction in Own Shares
14th Jan 202010:03 amRNSNet Asset Value(s)
6th Jan 20203:48 pmRNSIntention to launch an Offer
2nd Jan 20209:47 amRNSTotal Voting Rights
16th Dec 201911:15 amRNSTransaction in Own Shares
11th Dec 201911:02 amRNSNet Asset Value(s)
4th Dec 20197:54 amRNSFinal Results
15th Nov 201912:21 pmRNSDirector Declaration
12th Nov 201910:31 amRNSNet Asset Value(s)
1st Nov 20199:48 amRNSTotal Voting Rights
16th Oct 201912:08 pmRNSTransaction in Own Shares
11th Oct 20199:54 amRNSNet Asset Value(s)
1st Oct 20199:26 amRNSTotal Voting Rights
11th Sep 20195:02 pmRNSTransaction in Own Shares
6th Sep 201910:07 amRNSNet Asset Value(s)
2nd Sep 20191:13 pmRNSTotal Voting Rights
14th Aug 201911:53 amRNSDirector/PDMR Shareholding
9th Aug 20195:59 pmRNSTransaction in Own Shares
9th Aug 201911:15 amRNSDividend Reinvestment Scheme

Due to London Stock Exchange licensing terms, we stipulate that you must be a private investor. We apologise for the inconvenience.

To access our Live RNS you must confirm you are a private investor by using the button below.